

# *A Korean patent status database for medicines and/or vaccines*

October 2024




# Organization



Korean Intellectual  
Property Office

Provision of patent  
information



Ministry of Food and  
Drug Safety

❖ Examines pharmaceutical patent applications.

❖ Manages the **KIPRIS system**, which provides **detailed patent and trial information**\*

❖ **Handles** pharmaceutical approvals and manages the **Drug Patent List**.

❖ Operates a search system providing **patent information** for **approved pharmaceuticals**.

\*e.g., registered patentee, patent number, patent term expiration date, patent status, family patent information, trial status, etc.

# The official website operated by MFDS

<https://nedrug.mfds.go.kr/eng/index>



Drug Infomation

Laws/Data

Notice/Announcement/Notification



## Drug Approval by MFDS

Search



Drug Information  
Search

National Lot  
Release

Review  
Result

Document Authenticity  
Verification

# The official website operated by MFDS



Drug Safety

Drug Information

Laws/Data

Notice/Announcement/Notification



## Site Map

### Drug Information

Generic Drugs



Drug and Cosmetics Item Information



Domestic and Overseas Drug Patent Information



Other Information



### Laws/Data

Integrated Data Room



### Notice/Announcement/Notification

COVID-19 Related Approvals and Permission



Drug Patent List



• Drug Patent List


# The official website operated by MFDS

## Drug Patent List

Drug name	Major ingredient name
<input type="text"/>	<input type="text"/>
Approval code	Patent number
<input type="text"/>	<input type="text"/>
Registered patentee	Registration date
<input type="text"/>	<input type="text"/> ~ <input type="text"/>
Expiry date	Deletion date
<input type="text"/> ~ <input type="text"/>	<input type="text"/> ~ <input type="text"/>
Change date	Expired patent
<input type="text"/> ~ <input type="text"/>	<input type="checkbox"/>

Total **3,646**

 [Excel Download](#)

Display 10 results per page 

# Actual search example


## Drug Patent List

Drug name	Major ingredient name
<input type="text" value="Wegovy"/>	<input type="text"/>
Approval code	Patent number
<input type="text"/>	<input type="text"/>
Registered patentee	Registration date
<input type="text"/>	<input type="text"/> ~ <input type="text"/>
Expiry date	Deletion date
<input type="text"/> ~ <input type="text"/>	<input type="text"/> ~ <input type="text"/>
Change date	Expired patent
<input type="text"/> ~ <input type="text"/>	<input type="checkbox"/>
<input type="button" value="Search"/> <input type="button" value="Reset"/>	

# Actual search example

Total **10**









 Excel Download

Display 10 results per page 

Numerical order	Drug name	Major ingredient name	Registered patentee	Patent number	Registraton date
					Patent term expiration date
1	Wegovy Pre-filled Pen 0.25(Semaglutide)	Semaglutide	Novo Nordisk Pharma Korea, Ltd.	10-1241862-0000	2024-02-23
					2027-02-03
2	Wegovy Pre-filled Pen 0.25(Semaglutide)	Semaglutide	Novo Nordisk Pharma Korea, Ltd.	10-1205272-0000	2024-02-23
					2028-08-05
3	Wegovy Pre-filled Pen 0.5(Semaglutide)	Semaglutide	Novo Nordisk Pharma Korea, Ltd.	10-1241862-0000	2024-02-23
					2027-02-03
4	Wegovy Pre-filled Pen 0.5(Semaglutide)	Semaglutide	Novo Nordisk Pharma Korea, Ltd.	10-1205272-0000	2024-02-23
					2028-08-05
5	Wegovy Pre-filled Pen 1.0(Semaglutide)	Semaglutide	Novo Nordisk Pharma Korea, Ltd.	10-1241862-0000	2024-02-23
					2027-02-03
6	Wegovy Pre-filled Pen 1.0(Semaglutide)	Semaglutide	Novo Nordisk Pharma Korea, Ltd.	10-1205272-0000	2024-02-23
					2028-08-05

# Actual search example

## Drug Patent List


Drug name	<input type="text"/>	Major ingredient name	<input type="text" value="Semaglutide"/>
Approval code	<input type="text"/>	Patent number	<input type="text"/>
Registered patentee	<input type="text"/>	Registration date	<input type="text"/>  ~ <input type="text"/> 
Expiry date	<input type="text"/>  ~ <input type="text"/> 	Deletion date	<input type="text"/>  ~ <input type="text"/> 
Change date	<input type="text"/>  ~ <input type="text"/> 	Expired patent	<input type="checkbox"/>
<input type="button" value="Search"/>		<input type="button" value="Reset"/>	



# Actual search example

Total **18**

 Excel Download

Display 10 results per page 




Numerical order	Drug name 	Major ingredient name 	Registered patentee 	Patent number 	Registraton date 
					Patent term expiration date 
11	Ozempic Pre-filled Pen(Semaglutide)	Semaglutide	Novo Nordisk Pharma Korea, Ltd.	10-1243648-0000	2024-02-22
					2024-11-18
12	Ozempic Pre-filled Pen(Semaglutide)	Semaglutide	Novo Nordisk Pharma Korea, Ltd.	10-1241862-0000	2024-02-22
					2027-02-03
13	Ozempic Pre-filled Pen(Semaglutide)	Semaglutide	Novo Nordisk Pharma Korea, Ltd.	10-1205272-0000	2024-02-22
					2028-08-05
14	Rybelsus Tab.(Semaglutide)	Semaglutide	Novo Nordisk Pharma Korea, Ltd.	10-2272671-0000	2024-02-22
					2034-05-02
15	Rybelsus Tab.(Semaglutide)	Semaglutide	Novo Nordisk Pharma Korea, Ltd.	10-2072202-0000	2024-02-22
					2033-03-15
16	Rybelsus Tab.(Semaglutide)	Semaglutide	Novo Nordisk Pharma Korea, Ltd.	10-1925620-0000	2024-02-22
					2031-12-16
17	Rybelsus Tab.(Semaglutide)	Semaglutide	Novo Nordisk Pharma Korea, Ltd.	10-1241862-0000	2024-02-22
					2027-02-03
18	Rybelsus Tab.(Semaglutide)	Semaglutide	Novo Nordisk Pharma Korea, Ltd.	10-1205272-0000	2024-02-22
					2028-08-05

# Patent information search site, KIPRIS

<http://eng.kipris.or.kr/enghome/main.jsp>

The screenshot shows the top navigation bar of the KIPRIS website. The main navigation menu includes 'SEARCH', 'TODAY KIPRIS', 'PR', 'GUIDE', and 'KIPRIS'. Below this, a secondary menu highlights 'Patent', 'Design', 'Trademark', and 'KPA'. The central area features the KIPRIS logo and the tagline 'Korea Intellectual Property Rights Information Service'. A search bar is present with a dropdown menu set to 'All', a 'Search History' button, and a search icon. Below the search bar, a 'Popular Searches' section lists categories like 'ENERGY' and 'ENTERTAINMENT' with associated patent numbers.



 <b>Beginner's Program</b> Guided Search for Beginners	 <b>Korean IP Translation companies</b>	 <b>KIPRIS</b> Introduction to KIPRIS
---	---	--

**NOTICE** >more |

[Notice] KIPO's IP Data Download Service	2024-09-26
KPA Bibliography is now available(Patent ...	2024-09-20
KPA Bibliography is now available(Patent ...	2024-08-13
KPA Bibliography is now available(Patent ...	2024-07-08

# Patent information search site, KIPRIS

KIPRIS

SEARCH

TODAY KIPRIS

PR

GUIDE

KIPRIS

Patent

Design

Trademark

KPA

Eng-Kor

All

102272671

Spread



Search within Search Results

Search History

Integrated Search

All Results : 1Articles

Patent : 1Articles

Design : 0Articles

Trademark : 0Articles

Patent

Design

Trademark

KPA

New to KIPRIS?

Visit Search Guide for beginners and learn to search

Search Guide

Smart Search >

Click here! for advanced search

auto scroll off



Print

[Patent & Utility model] 1 Articles

Registered ORAL DOSING OF GLP-1 COMPOUNDS(GLP-1 화합물의 경구 투여)

PUB



IPC : A61K 38/26 A61K 31/166 ...

Applicant : NOVO NORDISK A/S

Application No. : 1020157032843

Application Date : 2014.05.02

Registration No. : 1022726710000

Registration Date : 2021.06.29

Unex. Pub. No. : 1020160002945

Unex. Pub. Date : 2016.01.08

Agent : Y.S.CHANG & ASSOCIAT...

Inventor : NIELSEN, Flemming Seier | SAUERBERG, Per

More

Integrated Search More

Patent & Utility More

[Design]

results are not be found

[Trademark]

results are not be found

Help

Q&A

Real-time popular keyword

Today KIPRIS

- 120111001...
- 대우자동차
- 은
- 이
- 을
- 는
- 가
- 조거팬츠
- 니트
- 가방

TOP

NEW

# Patent information search site, KIPRIS

## ORAL DOSING OF GLP-1 COMPOUNDS

GLP-1 화합물의 경구 투여

Details Unexam. Full Text Publ. Full Text Registr. Details Administrative

Details Biographical Information Legal Status **Claim** Designated States Citation Family Patent

Machine Translation 

No.	Content
1	<p>경구 투여에 의한 의약으로서 사용하기 위한 GLP-1 펩티드와 인헨서를 포함하는 고체 조성물로서, 상기 인헨서는 N-(8-(2-하이드록시벤조일)아미노)카프릴산의 염이고, 이때</p> <p>a) 상기 펩티드는 인간에서 적어도 60시간의 혈장 반감기를 가지고, 상기 펩티드는 세마글루타이드이고;</p> <p>b) 상기 조성물은 적어도 3회 투여되며; 및</p> <p>c) 상기 조성물은 상기 펩티드의 며칠 동안의 인간에서의 혈장 반감기와 상기 조성물의 며칠 동안의 투여 간격 사이의 비율이 2:1 보다 크도록 투여되는 고체 조성물.</p>
2	<p>제 1항에 있어서, 상기 조성물은 적어도 격일로 투여되는 것을 특징으로 하는 조성물.</p>
3	<p>제 1항에 있어서, 상기 조성물은 하루에 2회, 하루에 1회 또는 격일로 투여되는 것을 특징으로 하는 조성물.</p>
4	<p>제 1항에 있어서, 상기 조성물은 정제의 형태로 존재하는 것을 특징으로 하는 조성물.</p>
5	<p>제 1항에 있어서, 상기 조성물은 적어도 5회, 적어도 7회 또는 적어도 10회 투여되는 것을 특징으로 하는 조성물.</p>
6	<p>제 1항에 있어서, 상기 인헨서는 나트륨 N-(8-(2-하이드록시벤조일)아미노)카프릴레이트(SNAC)인 것을 특징으로 하는 조성물.</p>
7	<p>제 6항에 있어서, SNAC의 양은 100 내지 500mg의 SNAC이거나 또는 SNAC의 양은 상기 조성물의 50 내지 90%(w/w)인 것을 특징으로 하는 조성물.</p>
8	<p>제 1항에 있어서, 상기 펩티드는 0.01 내지 100mg, 2 내지 60mg, 적어도 5mg 또는 적어도 10mg의 양으로 투여되는 것을 특징으로 하는 조성물.</p>
9	<p>제 1항에 있어서, 상기 펩티드는 세마글루타이드이고, 상기 인헨서는 SNAC이고, 상기 조성물은 1 내지 100mg의 세마글루타이드와 100 내지 500mg 또는 50 내지 90%(w/w)의 SNAC을 포함하거나, 또는 상기 조성물은 2 내지 60mg의 세마글루타이드와 200 내지 400mg의 SNAC을 포함하는 것을 특징으로 하는 조성물.</p>


# Patent information search site, KIPRIS

## ORAL DOSING OF GLP-1 COMPOUNDS

GLP-1 화합물의 경구 투여

**Details** Unexam. Full Text Publ. Full Text Registr. Details Administrative

Details Biographical Information Legal Status **Claim** Designated States Citation Family Patent

Original Text 

No.	Content
1	<p>As the medicine by the oral administration, the solid composition in which the enhancer is the salt of N - (8 - (2-hydroxybenzoyl) amino) caprylic acid as the solid composition and :</p> <p>and c) composition the rate between the medication interval for the few days of the blood plasma half-life at the human for the few days of the peptide and the composition are administered while the peptide is the horse for hire glue tied and the then</p> <p>a) peptide :</p> <p>b) composition is administered in human with the blood plasma half-life of at least 60 hours with at least 3 times in order to be large than 2:1 including the GLP-1 peptide and the enhancer for using.</p>
2	As for claim 1, the composition in which the composition is administered to at least day's interval.
3	As for claim 1, the composition in which the composition is administered into day to two times, and day to 1 time or the day's interval.
4	As for claim 1, the composition in which the composition exists in the form of the refinement.
5	As for claim 1, the composition in which the composition is administered with at least 5 time, and at least 7 time or at least 10 time.
6	As for claim 1, the composition in which the enhancer is the sodium N - (8 - (2-hydroxybenzoyl) amino) caprylate (SNAC).
7	As for claim 6, amount of SNAC may be SNAC of 100 to 500mg. And the composition in which or amount of SNAC is 50 of the composition through 90 % (w/w).
8	As for claim 1, the composition in which the peptide is administered in an amount of 0.01 through 100mg, 2 through 60mg, and at least 5mg or at least 10mg.



특허청

Korean Intellectual Property Office

***Thank you!***